How to Talk About Drug Prices
A Reference Guide for Lawmakers The rising cost of prescription drugs is a top issue for voters this election cycle. AAM developed a resource for lawmakers, “How to Talk About Drug Prices: A Reference Guide for Effective Communications Strategy.” This primer on rising drug costs outlines how high launch prices and year-over-year price increases are […]
AAM Statement: Preserving Patient Access to Low-Cost Medicines Through COVID-19 and Beyond
WASHINGTON, DC (March 24, 2020) — The Association for Accessible Medicines (AAM) and its member companies express our steadfast support for all who are battling COVID-19, from the patients diagnosed with the disease to the health care professionals providing their care. For our part, generic and biosimilar manufacturers are committed to serving as a trusted […]
The First (Price) Cut Is the Steepest
Congress Must Preserve the 180-Day Incentive for First Generics In the debate over how to lower the cost of prescription drugs, one thing is certain: Generic competition drives savings for America’s patients and our health care system. The introduction of generic medicines offers patients the same high-quality medicine as the brand-name drug, but at an […]
Savings by Condition: The Latest Data
How much do you save when you treat your health conditions using generic drugs? The “Case for Competition”—the 11th annual edition of our Savings and Access Report—explores how generics and biosimilars bring down overall health care costs. To supplement the data in the report, the Association for Accessible Medicines (AAM) has also gathered information specific […]
AAM Statement on Avalere Analysis of Generic Substitution
WASHINGTON DC (January 23, 2020) –“Today’s report highlights the need to refine the Medicare program to support savings through generic drug substitution. The continued use of high-cost brand drugs instead of generics causes higher spending for patients and taxpayers.” ATTRIBUTE TO: Chip Davis, President and CEO Read White Paper MEDIA CONTACT: Rachel Schwartz 202.249.7147 […]
AAM Statement on “The Unintended Economics of the BLOCKING Act” Report
WASHINGTON DC (January 8, 2020) – New analysis from Matrix Global Advisors estimates the delay of just one generic medicine will increase prescription drug costs for patients by $1.7 billion. Congress should take the significant economic impact of the BLOCKING Act into account and reevaluate the need for this legislation. Without changes, the BLOCKING Act threatens […]
AAM Statement on HR 3
The Elijah E. Cummings Lower Drug Costs Now Act WASHINGTON DC (December 13, 2019) – AAM commends the House for its efforts to address the high cost of brand-name drugs and improve the Medicare program for seniors. Generics and biosimilars are vital to reducing spending for patients and taxpayers, and any inflation-based rebates should acknowledge the […]
AAM Opposes the Lower Health Care Costs Act
Legislation will harm generic drug competition WASHINGTON DC (December 9, 2019) – “AAM opposes the Lower Health Care Costs Act, because its inclusion of the BLOCKING Act will reduce generic drug competition, result in fewer affordable generic medicines being available to patients and thus will keep drug prices high. AAM has offered numerous alternatives to […]
AAM Launches #DoesntAddUp Ad Campaign to Bring Down Prescription Drug Costs for Patients in the U.S.
Patient Cost Rising While Generic Prices Fall Doesn’t Add Up WASHINGTON DC (October 23, 2019) – The Association for Accessible Medicines (AAM) today launched its seven-figure #DoesntAddUp advertising campaign to raise awareness among policymakers of the generic and biosimilar industry’s significant market access challenges and promote potential solutions to ensure patients can access their medicines. […]
2019 Generic Drug and Biosimilars Access & Savings in the U.S. Report
Overview To view the latest data, view 2020 Access & Savings Report 2019 Generic Drug and Biosimilars Access and Savings in the U.S. The 11th annual edition of AAM’s Savings and Access Report quantifies how much money American patients and our health care system are saving because of generic and biosimilar alternatives to brand-name prescription […]
AAM Statement on Generic and Biosimilar Drugmaker Inability to Acquire Samples
“Patients, payers and the government all lose when some brand manufacturers misuse FDA safety protocols to withhold samples from generic and biosimilar drugmakers, which delays market competition and keeps drug prices artificially high. Sample medicines are needed by the generic and biosimilar companies to conduct product development and bioequivalence studies necessary for FDA approval. The […]
AAM White Paper: Ensuring the Future of Accessible Medicines in the U.S.
Patient health and well-being depends on the uninterrupted availability of lower-cost generic and biosimilar medicines. Moreover, as patients live longer the importance of a robust and sustainable generic and biosimilar medicines industry becomes only that much more important. Policymakers must act quickly to ensure continued saving and market-based competition, as well as prevent shortages, for […]
